Dr. Vlock on Anti–CD20 Interleukin-2 Immunocytokine in NHL
Daniel R. Vlock, MD, founder and CEO, Alopexx Enterprises
, discusses a phase I/II study of an anti–CD20 interleukin-2 immunocytokine in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
, discusses a phase I/II study of an anti–CD20 interleukin-2 immunocytokine in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).Read more here.